Vivos Therapeutics Inc Stock Price, News & Analysis

Vivos Therapeutics (NASDAQ: VVOS) will release its third quarter 2025 financial results after market close on Wednesday, November 19, 2025. The company will host a conference call and webcast at 5:00 pm Eastern on November 19, 2025 to review results and provide operational updates, including discussion of strategic collaborations and their anticipated effect on near-term revenue growth and cash burn. A replay will be available through December 3, 2025, and the webcast archive will remain on the company website for 30 days.

Vivos Therapeutics (NASDAQ:VVOS) has released new clinical data demonstrating significant improvements in children with ADHD and OSA using their FDA-cleared Daytime-Nighttime Appliance (DNA). The study showed remarkable results, including a 50% decrease in pediatric sleep issues and a 58% decrease in ADHD symptoms.

The clinical trial, involving 48 children with an average age of 10.6 years, demonstrated 100% of patients experienced increased transpalatal width (+13.6%) and airway volume (+40%), while OSA severity decreased by 51.4%. The DNA appliance represents the only FDA-cleared non-surgical, non-pharmaceutical treatment for moderate to severe pediatric OSA in children ages 6-17.

The majority of improvements occurred within the first six months of treatment, offering a promising alternative to traditional adenotonsillectomy surgery and pharmaceutical interventions.

Vivos Therapeutics (NASDAQ: VVOS) announced groundbreaking results from a multicenter clinical trial for their DNA (Daytime-Nighttime Appliance®) device in treating pediatric obstructive sleep apnea (OSA). Published in the European Journal of Pediatrics, the study demonstrated significant efficacy with 77% of participants achieving at least 50% reduction in OSA severity, and 93% improvement rate in severe cases.

The trial revealed an average 67.8% increase in airway volume and 17% complete OSA resolution. This non-surgical alternative challenges the current standard adenotonsillectomy surgery, which is only effective in 20-40% of cases. The DNA appliance, part of Vivos' C.A.R.E. line, addresses a critical need as up to 20.4% of U.S. children suffer from OSA, with 90% remaining undiagnosed.

Vivos Therapeutics (NASDAQ:VVOS), a medical device company focused on sleep-related breathing disorders, reported Q2 2025 financial results marked by a strategic pivot in their business model. The company completed the acquisition of The Sleep Center of Nevada (SCN), generating approximately $500,000 in diagnostic sleep testing revenue in just 20 days.

Q2 2025 financial highlights include revenue of $3.8 million (down from $4.1M in Q2 2024), gross profit of $2.1 million with a 55% margin, and increased operating expenses of $7.0 million. The company ended the quarter with $4.4 million in cash. Additionally, Vivos entered into its first management agreement with MISleep Solutions LLC in Michigan, demonstrating progress in their updated sleep practice management model.

Vivos Therapeutics (NASDAQ:VVOS), a medical device and technology company focused on sleep-related breathing disorders treatment, has scheduled its Q2 2025 financial results release for August 19, 2025, after market close.

The company will host a conference call at 5:00 PM ET to discuss the results and provide updates on recent milestones. Investors can access the call via phone or webcast, with replay available until September 2, 2025.

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on treating obstructive sleep apnea (OSA), has announced two strategic executive appointments to support its expansion plans. Michael E. Bruhn joins as Executive Vice President of Business Operations Integration, while Dr. Terry Jones becomes Senior Vice President of Human Resources.

Bruhn, formerly EVP and COO at the United States Institute of Peace, will focus on expanding Vivos' operations in the Eastern United States and managing acquisitions integration, including the recent Sleep Center of Nevada acquisition. Dr. Jones, with over 20 years of leadership experience across federal agencies and private sector, will lead human resources strategy to support the company's growth phase.

Both executives will report directly to CEO R. Kirk Huntsman as Vivos implements its new business model focused on sleep testing centers and direct patient treatment operations.

Vivos Therapeutics (NASDAQ: VVOS) has achieved a significant milestone as its VidaSleep™ oral appliance received approval from the Centers for Medicare & Medicaid Services (CMS) for treating mild to moderate obstructive sleep apnea (OSA) and snoring in adults.

The VidaSleep™ device, featuring Vivos' patented and FDA-cleared Unilateral Bite Block technology, joins the company's mmRNA® device on the PDAC list of covered oral appliances. This dual-PDAC approval makes Vivos the only company with two Medicare-covered oral appliances, expanding access to millions of Medicare beneficiaries.

With an estimated 80 million Americans affected by OSA and over 80% of cases undiagnosed, Vivos is targeting the $36 billion sleep therapy market. The VidaSleep™ device is designed to offer a cost-effective solution without compromising efficacy, maintaining strong gross margins while expanding accessibility through Medicare and commercial insurance networks.

Vivos Therapeutics (NASDAQ: VVOS) announced the publication of groundbreaking clinical trial results in the European Journal of Pediatrics, demonstrating the effectiveness of their Daytime-Nighttime Appliance (DNA) in treating pediatric obstructive sleep apnea (OSA). The study showed 79% of patients experienced OSA improvement, with 61.7% improving by 50% or more.

The trial results validate Vivos' FDA 510(k) clearance received in September 2024 for treating moderate to severe OSA in children. Notably, 93% of children with severe OSA saw symptoms decrease by at least 50%. The DNA device presents a non-surgical alternative to adenotonsillectomy, which has a 68% symptom relapse rate within three years.

Vivos Therapeutics (NASDAQ: VVOS) has completed the acquisition of The Sleep Center of Nevada (SCN), marking a significant pivot in its business model. The $6M cash and $1.5M stock deal includes potential additional $1.5M in stock based on performance milestones. SCN, Nevada's largest sleep testing center, sees 3,000 new patients monthly and generates high seven-figure annual revenues. The acquisition was financed through an $8.225M secured loan from Streeterville Capital and a $3.755M private placement from New Seneca Partners. This strategic move shifts Vivos from a dental provider network model to directly managing sleep practices, allowing immediate capture of OSA diagnostic revenue and treatment opportunities. SCN's network of seven locations and 50 beds for sleep testing, led by Dr. Prabhu Rachakonda and Dr. Tara Rachakonda, will now offer Vivos' FDA-cleared OSA treatments to patients, with full integration expected over 12-18 months.